Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncology Pharma Inc ONPH

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals... see more

Recent & Breaking News (GREY:ONPH)

Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.

Accesswire August 19, 2021

Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP

Accesswire July 20, 2021

Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase

Accesswire June 30, 2021

Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties

Accesswire June 15, 2021

Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform

Accesswire June 9, 2021

Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer

Accesswire May 18, 2021

Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange

Accesswire May 12, 2021

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

Accesswire May 7, 2021

Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform

Accesswire April 21, 2021

Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology

Accesswire April 14, 2021

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

Accesswire April 7, 2021

Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities

GlobeNewswire March 31, 2021

Oncology Pharma Reveals Strategic Plans for Company Growth and Focus

GlobeNewswire March 16, 2021

Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy

GlobeNewswire March 10, 2021

Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies

GlobeNewswire March 4, 2021

Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

GlobeNewswire February 26, 2021

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

GlobeNewswire February 22, 2021

Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board

GlobeNewswire February 16, 2021

Oncology Pharma Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform

GlobeNewswire February 9, 2021

Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

GlobeNewswire February 3, 2021